Member Info for Alwaysone

I'm afraid it will be before Winter imho. It's good that MOST people are still practising social distancing but many aren't, aside from generally which I see, look at the protesting in thousands here and especially the US, I cringe. Many have forgotten how deadly this virus is and we'll pay for it in the next couple of months but I do hope that I am wrong.

Sellers are going to regret it, just watch today and until Friday close..... few seem to know what investing is, but if peeps have doubled their investment, why not top slice, bag some profits, all sensible stuff

I did say a few days back, Punit doesn't have a clue from seeing hin on GDR, just filter him

Tiziana Life Sciences stem cell tool superior to market leader Exact Sciences' Oncotype DX in breast cancer head to head

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has said that two poster presentations at a top medical conference underline the potential of its technology in predicting the recurrence of breast cancer.
https://www.proactiveinvestors.co.uk/companies/news/920682/tiziana-life-sciences-stem-cell-tool-superior-to-market-leader-exact-sciences---oncotype-dx-in-breast-cancer-head-to-head-920682.html

The group's StemPrintER stem cell-based genomic prognostic tool showed superiority over the market leader, Oncotype DX, developed by Exact Sciences (NASDAQ:EXAS), when it came to predicting the recurrence of the disease in ER+/HER2- postmenopausal patients.

https://www.proactiveinvestors.com/companies/news/920902/tiziana-life-sciences-plc-s-chairman-discusses-the-potential-for-its--crown-jewel--foralumab-drug-920902.html
Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone tells Proactive London's Andrew Scott why he feels its drug Foralumab is the 'crown jewel' in the company's portfolio.

It's a fully-human monoclonal anti-CD3 antibody which is being developed for treatment of inflammatory and autoimmune diseases.

Cerrone says the drug potentially addresses by far the largest markets of any of the drugs in its pipeline.

Tiziana's looking to launch Phase II trials in Crohn's Disease and MS around the end of June or early July and Cerrone says that'll put them on the path to once and for all seeing whether one of these two indications has efficacy.

''The potential turnover you can have for a monoclonal antibody is multi-billions per indication'', he says.

2 Wall Street analysts have issued ratings and price targets for Tiziana Life Sciences in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 251.56%. The high price target for TLSA is $25.00 and the low price target for TLSA is $20.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

https://www.marketbeat.com/stocks/NASDAQ/TLSA/price-target/
5/29/2020 HC Wainwright Reiterated Rating Buy $25.00 Low
9/10/2019 Laidlaw Set Price Target Buy $20.00 N/A

Ignore trades during the day Punit, many large trades are delayed, sometimes a day.
I often find them a bit of a waste of time anyway, MMs still control except when massive demand one way or another
US are pricing ahead of us.....until close of their day, they shoudl drop theoretically -- or we bounce at close, which I dount
AVCT down 13 % but have had a massive ride up to £2...

There was a small gap at £1.04 on 28 May on the spike up, it's now been filled

What RNS and who, Quilter finally?

Noted that 2018's were early April 2019 but nothing has come up for 2019 as yet.
Odly, on one of my charts, it has Upcoming earnings report in 2 days...

Financial Results for the Year Ended 31 December 2018

@Safy - I just wondered what " #TILS just touched the 8ema at 103p" meant.
The £1.20 point is total bollxxks of course. Not my mate, was just searching #TILS
The sector is weak today

Twitter - make sense?

HunterD
@confluencetradr
·
2h
#TILS just touched the 8ema at 103p. Hence expecting a strong bounce up to surpass 120p. Excellent buying opp. Just cant believe it's still down here. Should be in the 200s. Strong Buy!!!

@ jadam, yes I guess so, but to be honest, if you get a reply from Hannah, it will no doubt refer to the RNS.

Not sure why so much worry/questions on here!
AVCT down 15% at the moment, the faster upwards, the faster down......but not ITM yet.
Always good to look at what other Aim stocks are doing to get a feel / compare

I have to say, that I have never been keen on the ATM sales agreement. First we had Quilter pulling us back, then we;ll have a drip feed in the ATM. These pharma companies get through cash pretty quick. But for long term progression and to achive the huge potential I guess. This is why the price hasn't peaked too much on any one day though

WHY are you all so fixated with the POTENTIAL company split, when I keep showing the RNS that covers?
No record date has yet been set for the entitlement to shares in the new StemPrintER entity

Notwithstanding that the required approval for the capital reduction will be sought, these considerations remain at an early stage and there can be no guarantee that the demerger will be completed. The approval of the capital reduction will enable the Board, in due course, to declare distribution in specie of shares in the new StemPrintER entity to existing Tiziana shareholders.

No record date has yet been set for the entitlement to shares in the new StemPrintER entity as a number of technical, legal and accounting processes need to be completed before the demerger can be formally put to shareholders of Tiziana for approval. For the avoidance of doubt StemPrintER will remain a group business until such time as shareholders formally approve proposals for a demerger.

Well said CP. Great summary. No share is a 100% guaranteed winner but TILS is as close to being that in my opinion. Buy and just hold for huge profits. Ignore the noise and daily trading.

What I don’t understand with the ATM that started in
May, is how do ADRs get traded on the London market, any ideas? It even states amounts in dollars.

During the calendar month of May, the Company issued a total of 1,743,445 ordinary shares under the Company's ATM sales agreement announced on 15 April 2020 to meet sales of a total of 348,689 ADSs under the ATM sales agreement, totaling gross proceeds of $1,985,004. Those ordinary shares were admitted to trading on AIM under the Company's "US ADS ATM Placing Scheme" block listing.

Brilliant interview, what incredible potential this company has in many areas with potential for £billions of turnover
Can’t help thinking that one of the big boys will make a bid to takeover but I’d rather we stay as we are. HUGE multipliers of share price to imho

What I don’t understand with the ATM that started in
May, is how do ADRs get traded on the London market, any ideas? It even states amounts in dollars.

During the calendar month of May, the Company issued a total of 1,743,445 ordinary shares under the Company's ATM sales agreement announced on 15 April 2020 to meet sales of a total of 348,689 ADSs under the ATM sales agreement, totaling gross proceeds of $1,985,004. Those ordinary shares were admitted to trading on AIM under the Company's "US ADS ATM Placing Scheme" block listing.